Trastuzumab deruxtecan
Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd) . Trastuzumab deruxtecan has an improved effect on the treatment of HER2-positive breast cancer and gastric cancer.
Product Specifications
CAS Number
1826843-81-5
Stability
≥ 2 years
Purity
>98% (HPLC)
Weight
Approximately 45.42 kDa
Molecular Formula
——
Notes
Research use only, not for human use.
Receptor
Antibody-Drug Conjugates (ADCs)
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
B2709-01D1-ML490 100 µL
BRCA1, phospyhorylated (Ser1423) (Breast Cancer 1, Early Onset, Breast-Ovarian Cancer Susceptibility) (MaxLight 490) discontinued
Ask
View Details 
